Literature DB >> 15041079

Transforming growth factor-beta (TGF-beta)-resistant B cells from chronic lymphocytic leukemia patients contain recurrent mutations in the signal sequence of the type I TGF-beta receptor.

William P Schiemann1, Diana Rotzer, Waither M Pfeifer, Edi Levi, Kanti R Rai, Petra Knaus, Marshall E Kadin.   

Abstract

B cell chronic lymphocytic leukemia (B-CLL) is the most common leukemia in western societies, and is currently incurable. B cells of some B-CLL patients are resistant to the anti-proliferative effects of transforming growth factor-beta (TGF-beta). Herein, we identified two mutations within the putative signal sequence of TGF-beta type I receptor (TbetaR-I) gene of TGF-beta-resistant B-CLL patients (i.e., a Leu12Gln substitution together with an in-frame single Ala deletion). Although TbetaR-I mutants were expressed to the cell surface and interacted normally with TGF-beta-bound TbetaR-II, their expression significantly reduced gene transcription stimulated by TGF-beta, suggesting a causal relationship in the development of TGF-beta-resistant B-CLL. Screening of additional B-CLL patients solely for the presence of TbetaR-I signal sequence mutations showed that these mutations correlated with and predicted for B-CLL patient insensitivity to TGF-beta. Our results demonstrate that TGF-beta-resistant B-CLL is linked to signal sequence mutations within the TbetaR-I gene, and may eventually be employed as a prognostic indicator in B-CLL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15041079     DOI: 10.1016/j.cdp.2003.11.001

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  11 in total

Review 1.  Signaling Receptors for TGF-β Family Members.

Authors:  Carl-Henrik Heldin; Aristidis Moustakas
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-08-01       Impact factor: 10.005

Review 2.  Transforming growth factor-β and the hallmarks of cancer.

Authors:  Maozhen Tian; Jason R Neil; William P Schiemann
Journal:  Cell Signal       Date:  2010-11-06       Impact factor: 4.315

3.  Detection, analysis and clinical validation of chromosomal aberrations by multiplex ligation-dependent probe amplification in chronic leukemia.

Authors:  Adam Abdool; Amber C Donahue; Jay G Wohlgemuth; Chen-Hsiung Yeh
Journal:  PLoS One       Date:  2010-10-25       Impact factor: 3.240

Review 4.  Role of transforming growth factor-beta in hematologic malignancies.

Authors:  Mei Dong; Gerard C Blobe
Journal:  Blood       Date:  2006-02-16       Impact factor: 22.113

5.  Identification and characterization of regulator of G protein signaling 4 (RGS4) as a novel inhibitor of tubulogenesis: RGS4 inhibits mitogen-activated protein kinases and vascular endothelial growth factor signaling.

Authors:  Allan R Albig; William P Schiemann
Journal:  Mol Biol Cell       Date:  2004-11-17       Impact factor: 4.138

6.  Human Marfan and Marfan-like Syndrome associated mutations lead to altered trafficking of the Type II TGFβ receptor in Caenorhabditis elegans.

Authors:  Jing Lin; Mehul Vora; Nanci S Kane; Ryan J Gleason; Richard W Padgett
Journal:  PLoS One       Date:  2019-05-09       Impact factor: 3.240

7.  The multifunctional adaptor protein HIP-55 couples Smad7 to accelerate TGF-β type I receptor degradation.

Authors:  Yang Sun; Zi-Jian Li
Journal:  Acta Pharmacol Sin       Date:  2021-07-30       Impact factor: 6.150

Review 8.  TGF-β - an excellent servant but a bad master.

Authors:  Lenka Kubiczkova; Lenka Sedlarikova; Roman Hajek; Sabina Sevcikova
Journal:  J Transl Med       Date:  2012-09-03       Impact factor: 5.531

9.  Characterization of novel transforming growth factor-beta type I receptors found in malignant pleural effusion tumor cells.

Authors:  Kuo-Li Chen; Wan-Hsin Liu; Yi-Yuan Yang; Sy-Jye C Leu; Neng-Yao Shih
Journal:  BMC Mol Biol       Date:  2007-08-17       Impact factor: 2.946

10.  Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia.

Authors:  D Saulep-Easton; F B Vincent; M Le Page; A Wei; S B Ting; C M Croce; C Tam; F Mackay
Journal:  Leukemia       Date:  2014-03-18       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.